Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a global public health emergency, and new therapeutics are needed. This article reports the potential drug target and mechanism of action of Arbidol (umifenovir) to treat coronavirus disease 2019 (COVID-19). Molecular dynam...

Descripción completa

Detalles Bibliográficos
Autor principal: Vankadari, Naveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. and International Society of Chemotherapy. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187825/
https://www.ncbi.nlm.nih.gov/pubmed/32360231
http://dx.doi.org/10.1016/j.ijantimicag.2020.105998
_version_ 1783527231474106368
author Vankadari, Naveen
author_facet Vankadari, Naveen
author_sort Vankadari, Naveen
collection PubMed
description The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a global public health emergency, and new therapeutics are needed. This article reports the potential drug target and mechanism of action of Arbidol (umifenovir) to treat coronavirus disease 2019 (COVID-19). Molecular dynamics and structural analysis were used to show how Arbidol targets the SARS-CoV-2 spike glycoprotein and impedes its trimerization, which is key for host cell adhesion and hijacking, indicating the potential of Arbidol to treat COVID-19. It is hoped that knowledge of the potential drug target and mechanism of action of Arbidol will help in the development of new therapeutics for SARS-CoV-2.
format Online
Article
Text
id pubmed-7187825
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V. and International Society of Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-71878252020-04-28 Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein Vankadari, Naveen Int J Antimicrob Agents Short Communication The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a global public health emergency, and new therapeutics are needed. This article reports the potential drug target and mechanism of action of Arbidol (umifenovir) to treat coronavirus disease 2019 (COVID-19). Molecular dynamics and structural analysis were used to show how Arbidol targets the SARS-CoV-2 spike glycoprotein and impedes its trimerization, which is key for host cell adhesion and hijacking, indicating the potential of Arbidol to treat COVID-19. It is hoped that knowledge of the potential drug target and mechanism of action of Arbidol will help in the development of new therapeutics for SARS-CoV-2. Elsevier B.V. and International Society of Chemotherapy. 2020-08 2020-04-28 /pmc/articles/PMC7187825/ /pubmed/32360231 http://dx.doi.org/10.1016/j.ijantimicag.2020.105998 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Vankadari, Naveen
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
title Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
title_full Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
title_fullStr Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
title_full_unstemmed Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
title_short Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein
title_sort arbidol: a potential antiviral drug for the treatment of sars-cov-2 by blocking trimerization of the spike glycoprotein
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187825/
https://www.ncbi.nlm.nih.gov/pubmed/32360231
http://dx.doi.org/10.1016/j.ijantimicag.2020.105998
work_keys_str_mv AT vankadarinaveen arbidolapotentialantiviraldrugforthetreatmentofsarscov2byblockingtrimerizationofthespikeglycoprotein

Ejemplares similares